Read clinical evidence
Distinguish study findings, evidence limits and the steps still needed for commercial delivery.
Biopharma investing: from evidence to value
From a biopharma headline to a reasoned judgment.
First release: Chinese introduction, lesson 1 and exercisesA trial result, a licensing payment, an acquisition proposal: what has actually changed for the company? We work through real cases to connect clinical evidence, contracts, finances and share prices.
Turn numbers into questions you can investigate.
Unpack deals and financial figures
Separate upfront payments, milestones and royalties, then connect revenue, profit, cash flow and dilution.
Explain the basis for a judgment
Separate facts from assumptions, identify valuation inputs and decide what to verify next.
WHO IT IS FOR
Curious about medicines—and the companies behind them.
For readers of biopharma news who want a grounding in finances and deals, including those with medical or research backgrounds who want to connect clinical evidence with company disclosures. The course begins with foundational questions; prior valuation-model experience is not required.
Bring a story you are following: what happened, how far does the evidence go, and what might it mean for the company’s cash and value per share?
Seven foundation lessons
- 01
Why cash received is not always revenue
Chinese text and exercises are public · Audio in production
Read in Chinese → - 02
How payments work in a collaboration
Companion materials in preparation · Invited review
- 03
Borrowing, share issuance and dilution
Companion materials in preparation · Invited review
- 04
Profit and cash flow
Companion materials in preparation · Invited review
- 05
The quality of revenue growth
Companion materials in preparation · Invited review
- 06
From clinical evidence to commercial delivery
Companion materials in preparation · Invited review
- 07
Company prospects and the share price
Companion materials in preparation · Invited review
Keep practicing with real cases.
The first Chinese lesson, including diagrams and exercises, is public. Audio is in production. Later Chinese lessons, English lessons and case supplements remain in invited review and will open as their companion materials become ready.
STAY IN TOUCH
Get a launch notification →Receive one notice when the full course opens.
For one notice when the full course opens, choose “Biopharma investing course launch” on the signup page and confirm your email. Article-update subscriptions do not automatically include course notifications. You can manage your choices or unsubscribe at any time.
The course teaches how to interpret evidence, disclosures and valuation assumptions. It does not offer individual stock recommendations or promise investment returns. The first Chinese lesson is public; the directory records subsequent releases.